logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12527779 B1

PDFFull Text
Date of Patent:
Jan. 20, 2026

Filed:

Oct. 02, 2020

Prostaglandin e(pge) epreceptor antagonists

Applicant:

Domain Therapeutics, Illkirch-Graffenstaden, FR;

Inventors:

Anne-Laure Blayo, Illkirch-Graffenstaden, FR;

Ismet Dorange, Illkirch-Graffenstaden, FR;

Gaël Hommet, Illkirch-Graffenstaden, FR;

Baptiste Manteau, Illkirch-Graffenstaden, FR;

Stanislas Mayer, Illkirch-Graffenstaden, FR;

Stephan Schann, Illkirch-Graffenstaden, FR;

Assignee:

Domain Therapeutics, Illkirch-Graffenstaden, FR;

Attorney:

pH IP Law

Primary Examiner:

Kamal A Saeed

Assistant Examiner:

Sagar undefined Patel

Int. Cl.
CPC ...
A61K 31/453 (2006.01); A61K 31/196 (2006.01); A61K 31/341 (2006.01); A61K 31/351 (2006.01); A61K 31/382 (2006.01); A61K 31/40 (2006.01); A61K 31/4025 (2006.01); A61K 31/4155 (2006.01); A61K 31/4245 (2006.01); A61K 31/4418 (2006.01); A61K 31/4433 (2006.01); A61K 31/4439 (2006.01); A61K 31/4468 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07C 233/63 (2006.01); C07D 207/09 (2006.01); C07D 207/12 (2006.01); C07D 211/66 (2006.01); C07D 213/64 (2006.01); C07D 213/65 (2006.01); C07D 213/68 (2006.01); C07D 307/24 (2006.01); C07D 309/08 (2006.01); C07D 309/10 (2006.01); C07D 309/14 (2006.01); C07D 311/94 (2006.01); C07D 335/02 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 407/12 (2006.01); C07D 413/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/453 (2013.01); A61K 31/196 (2013.01); A61K 31/341 (2013.01); A61K 31/351 (2013.01); A61K 31/382 (2013.01); A61K 31/40 (2013.01); A61K 31/4025 (2013.01); A61K 31/4155 (2013.01); A61K 31/4245 (2013.01); A61K 31/4418 (2013.01); A61K 31/4433 (2013.01); A61K 31/4439 (2013.01); A61K 31/4468 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07C 233/63 (2013.01); C07D 207/09 (2013.01); C07D 207/12 (2013.01); C07D 211/66 (2013.01); C07D 213/64 (2013.01); C07D 213/65 (2013.01); C07D 213/68 (2013.01); C07D 307/24 (2013.01); C07D 309/08 (2013.01); C07D 309/10 (2013.01); C07D 309/14 (2013.01); C07D 311/94 (2013.01); C07D 335/02 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/12 (2013.01); C07D 413/12 (2013.01);
Abstract

The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them highly advantageous for use in therapy, particularly in the treatment or prevention of cancer, a neovascular eye disease, inflammatory pain, or an inflammatory disease, such as, e.g., multiple sclerosis, rheumatoid arthritis or endometriosis.

Find Patent Forward Citations

Loading…